CCA E Klatskin


  1. Gringeri E, Bassi D, D'Amico FE, Boetto R, Polacco M, D'Amico F, Vitale A, Boccagni P, Zanus G, Cillo U. Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival. Transplant Proc. 2011 May;43(4):1187-9.
  • Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma — a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–73.
  • Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24: 115–25.
  • Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:1–5.
  • Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004;99:523–6.
  • Shin HR, Lee CU, Park HJ, et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996; 25: 933–40.
  • Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003;37: 961–9.
  • Isomoto H, Mott JL, Kobayashi S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007;132:384–96.
  • Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis: an unusual tumor with distinctive clinical and pathological features. Am J Med 1965;38: 241–56.
  • Bach AM, Hann LE, Brown KT, Getrajdman GI, Herman SK, Fong Y, Blumgart LH. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology. 1996 Oct;201(1):149-54.
  • Hann LE, Getrajdman GI, Brown KT, et al. Hepatic lobar atrophy: association with ipsilateral portal vein obstruction. AJR Am J Roentgenol 1996;167:1017–21.
  • Greene FL, Page PD, Fleming ID, et al. AJCC cancer staging manual. 6th edition. New York: Springer-Verlag; 2002.
  • Matsuo K, Rocha FG, Ito K, D'Angelica MI, Allen PJ, Fong Y, Dematteo RP, Gonen M, Endo I, Jarnagin WR. The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg. 2012 Sep;215(3):343-55.
  • Lee JH, Hwang DW, Lee SY, Park KM, Lee YJ. The proximal margin of resected hilar cholangiocarcinoma: the effect of microscopic positive margin on long-term survival. Am Surg. 2012 Apr;78(4):471-7.
  • Nimura Y, Hayakawa N, Kamiya J, Knodo S, Shionoya S. Hepatic segmentectomy with caudate lobe resection for bile-duct carcinoma of the hepatic hilus. World J Surg 1990;14:535–44.
  • D'Angelica MI, Jarnagin WR, Blumgart LH. Resectable hilar cholangiocarcinoma: surgical treatment and long-term outcome. Surg Today. 2004;34(11):885-90.
  • Farges O, Fuks D, Le Treut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group Cancer. 2011 May 15;117(10):2170-7.
  • Endo I, Gonen M, Yopp AC, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008 Jul;248(1):84-96.
  • Chou FF, Sheen-Chen SM, Chen YS, Chen MC, Chen CL. Surgical treatment of cholangiocarcinoma. Hepatogastroenterology. 1997 May-Jun;44(15):760-5.
  • Nathan H, Pawlik TM, Wolfgang CL, et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg. 2007;11:1488 –1496.
  • Weber SM, Jarnagin WR, Klimstra D, et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg. 2001;193:384 –391.
  • Altro in questa categoria: « PROSPETTIVE FUTURE